Marinus On Track To Be Leader In Rare Epilepsy Market, Says CEO
Strategic Collaborations, Creative Financing And Late-Stage Data Readouts
CEO Scott Braunstein, who took leadership of Marinus in 2019 following clinical trial setbacks, believes the company is on a route to success with its ganaxolone program, targeting chronic use and hospital markets.
